- Home
- SGLY vs ENVB Comparison
SGLY vs ENVB Comparison
Compare SGLY & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- ENVB
- Stock Information
- Founded
- SGLY 2001
- ENVB 1994
- Country
- SGLY United States
- ENVB United States
- Employees
- SGLY N/A
- ENVB N/A
- Industry
- SGLY
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- ENVB Health Care
- Exchange
- SGLY Nasdaq
- ENVB Nasdaq
- Market Cap
- SGLY 3.7M
- ENVB 3.2M
- IPO Year
- SGLY 2008
- ENVB N/A
- Fundamental
- Price
- SGLY $0.92
- ENVB $1.30
- Analyst Decision
- SGLY
- ENVB Strong Buy
- Analyst Count
- SGLY 0
- ENVB 1
- Target Price
- SGLY N/A
- ENVB $10.00
- AVG Volume (30 Days)
- SGLY 457.6K
- ENVB 461.6K
- Earning Date
- SGLY 05-15-2025
- ENVB 05-14-2025
- Dividend Yield
- SGLY N/A
- ENVB N/A
- EPS Growth
- SGLY N/A
- ENVB N/A
- EPS
- SGLY N/A
- ENVB N/A
- Revenue
- SGLY $2,172,036.00
- ENVB N/A
- Revenue This Year
- SGLY N/A
- ENVB N/A
- Revenue Next Year
- SGLY N/A
- ENVB N/A
- P/E Ratio
- SGLY N/A
- ENVB N/A
- Revenue Growth
- SGLY N/A
- ENVB N/A
- 52 Week Low
- SGLY $0.54
- ENVB $1.01
- 52 Week High
- SGLY $7.65
- ENVB $11.82
- Technical
- Relative Strength Index (RSI)
- SGLY 50.30
- ENVB 45.17
- Support Level
- SGLY $0.82
- ENVB $1.11
- Resistance Level
- SGLY $1.03
- ENVB $1.34
- Average True Range (ATR)
- SGLY 0.14
- ENVB 0.10
- MACD
- SGLY -0.01
- ENVB 0.04
- Stochastic Oscillator
- SGLY 15.08
- ENVB 70.26
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.